US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.01 against a street estimate of 0.02 — a miss of 150.0%.
Analysts rate Xeris Pharmaceuticals Inc a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $12.29.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.10% |
| D. E. Shaw & Co LP | 4.28% |
| Vanguard Capital Management, LLC | 3.83% |
| State Street Corp | 2.55% |
| Geode Capital Management, LLC | 2.35% |
| Qube Research & Technologies | 2.26% |
| Rosalind Advisors, Inc. | 1.77% |
| Nuveen, LLC | 1.60% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 XERIS BIOPHARMA HOLDINGS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics, revenue figures, or numerical results disclosed | 2026-09-09 |
| Quarterly report · Q2 2026 XERIS BIOPHARMA HOLDINGS, INC. — Q2 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $175.2 million, up 33% vs. $131.7 million in | 2026-08-06 |
| Results announced · Q3 2026 XERIS BIOPHARMA Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue Q2 2026: $92.1 million, up 29% year-over-year from $71.5 million • Net pro | 2026-08-06 |
| Company announcement · Q3 2026 XERIS BIOPHARMA HOLDINGS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Approximately $23 million in convertible debt exchanged for 5.0 million common | 2026-07-17 |
| Board / officer change · Q2 2026 XERIS BIOPHARMA HOLDINGS, INC. — FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company appointed Dr. Nerissa Kreher, M.D., as a new independent d | 2026-06-30 |
| Company announcement · Q2 2026 XERIS BIOPHARMA HOLDINGS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company exchanging approximately $23 million in principal amount of convertible | 2026-06-11 |
| Quarterly report · Q1 2026 XERIS BIOPHARMA HOLDINGS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue Q1 2026: $83.1 million (vs. $60.1 million Q1 2025; +38% year- | 2026-05-07 |
| Proxy statement · Q4 2025 XERIS BIOPHARMA HOLDINGS, INC. – PROXY SUMMARY --- CEO TOTAL COMPENSATION & CHANGE • CEO John Shannon's total compensation figures are not disclosed | 2026-04-23 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Xeris Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.